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Abstract: Vildagliptin is a potent and selective inhibitor of dipeptidyl peptidase-IV (DPP-4), 
orally active, that improves glycemic control in patients with type 2 diabetes (T2DM) primarily 
by enhancing pancreatic (α and β) islet function. Thus vildagliptin has been shown both to 
improve insulin secretion and to suppress the inappropriate glucagon secretion seen in patients 
with T2DM. Vildagliptin reduces HbA1c when given as monotherapy, without weight gain and 
with minimal hypoglycemia, or in combination with the most commonly prescribed classes of 
oral hypoglycemic drugs: metformin, a sulfonylurea, a thiazolidinedione, or insulin. Metformin, 
with a different mode of action not addressing β-cell dysfunction, has been used for about 50 
years and still represents the universal ﬁ  rst line therapy of all guidelines. However, given the 
multiple pathophysiological abnormalities in T2DM and the progressive nature of the disease, 
intensiﬁ  cation of therapy with combinations is typically required over time. Recent guidelines 
imply that patients will require pharmacologic combinations much earlier to attain and sustain 
the increasingly stringent glycemic targets, with careful drug selection to avoid unwanted 
adverse events, especially hypoglycemia. The combination of metformin and vildagliptin 
offers advantages when compared to currently used combinations with additive efﬁ  cacy and 
complimentary mechanisms of action, since it does not increase the risk of hypoglycemia and 
does not promote weight gain. Therefore, by speciﬁ  cally combining these agents in a single 
tablet, there is considerable potential to achieve better blood glucose control and to improve 
compliance to therapy.
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Management of type 2 diabetes: use of metformin 
and the role of combination treatment
Type 2 diabetes (T2DM) is a chronic and complex disease which involves multiple 
pathophysiological defects, including impaired islet function and insulin resistance, 
resulting in impaired glucose tolerance and inappropriately high fasting hepatic glu-
cose production. While insulin resistance remains essentially unchanged over time, 
the deﬁ  cit in islet function is a progressive process with quantitative and qualitative 
abnormalities in insulin and glucagon secretion kinetics, paralleled by a substantial 
reduction in the maximum capacity to secrete insulin. These defects in islet function 
are present early on and worsen with the natural history of the disease (Butler et al 
2003; Nathan et al 2007; Virally et al 2007). Indeed, most individuals who are insulin 
resistant never develop T2DM because normal islets adapt to insulin resistance both 
by increasing glucose-potentiated insulin secretion (Kahn et al 1993) and by increas-
ing α-cell sensitivity to the suppressive effects of glucose (Ahren 2006). Thus, the Vascular Health and Risk Management 2008:4(3) 482
Halimi et al
ﬁ  rst patent characteristic of T2DM is inadequate islet com-
pensation rather than absolute hypoinsulinemia or absolute 
hyperglucagonemia (Ahren et al 2008).
Despite clear evidence that maintenance of glycemic 
levels as close to normal as possible reduces the risk of dia-
betic complications, optimal control is seldom achieved and 
maintained in patients with T2DM (Brown et al 2004; Koro 
et al 2004). While all oral antidiabetic agents initially lower 
blood glucose effectively, none of them are able to address 
all the anomalies involved in the pathogenesis of T2DM, to 
stop the decline in beta-cell function, and to achieve durable 
glycemic control (Cook et al 2007).
Established management of T2DM starts with lifestyle 
changes, ie, introducing a healthier diet and increasing 
physical activity in order to improve glucose utilization 
and promote weight loss. This is accompanied by rapid or 
even concomitant introduction of an oral antidiabetic agent. 
Metformin is widely used as the ﬁ  rst-line antidiabetic drug 
of choice (Consoli et al 2004; Halimi 2006). Metformin 
reduces hepatic glucose output, primarily by inhibiting 
gluconeogenesis, and, to a lesser extent, increases tissue 
sensitivity to insulin (Stumvoll et al 1995). Beneﬁ  cial clini-
cal properties of metformin include weight control (Golay 
2007), a low risk of hypoglycemia and favorable effects on 
the lipid proﬁ  le and the ﬁ  brinolytic pathway (Bailey and 
Turner 1996; Goodarzi and Bryer-Ash 2005). Metformin 
was reported to be equally effective in lowering glucose in 
non-obese and obese patients and can thus be used indepen-
dent of an individual’s BMI (Donnelly et al 2006). More 
importantly, it is the only drug which has demonstrated 
beneﬁ  cial effects on cardiovascular events, as reported in 
the UKPDS substudy of overweight patients (UKPDS 34 
1998). In this study, metformin was also associated with 
reduced all cause mortality, which was not seen in patients 
with equally well controlled blood glucose treated with 
sulfonylureas or insulin.
Metformin is therefore recommended by all guidelines 
as ﬁ  rst-line therapy for T2DM. The International Diabetes 
Federation (IDF) suggests to use metformin in all cases 
inadequately controlled by non-pharmacological treatments 
(IDF, on line) while a recent consensus document of the 
American Diabetes Association (ADA) and the European 
Association for the Study of Diabetes (EASD) recommends 
to prescribe metformin at diagnosis, together with lifestyle 
interventions (Nathan et al 2006, 2008).
Upon progression of the disease, progressive loss of β-cell 
function and mass makes it difﬁ  cult for patients to maintain 
glycemic control with monotherapy. In the UKPDS only 
about 50% of patients were still adequately controlled on 
monotherapy after 3 years (Turner et al 1999) (UKPDS-49). 
Even if somewhat better durability of glycemic control was 
achieved with TZD over 4 years in the ADOPT trial (Kahn 
et al 2006), high rates of secondary failure have been reported 
with all current oral hypoglycemic drugs (OADs), includ-
ing following successful initial metformin therapy (Nichols 
et al 2006).
As a result, combination therapy involving agents with 
complementary mechanism of action is the next logical step 
in the management of T2DM. Established treatment options 
for metformin monotherapy failure include the addition of 
sulfonylureas (or glinides), thiazolidinediones, acarbose, 
or insulin. Since metformin lowers plasma glucose without 
affecting insulin secretion, it is often combined with an 
agent stimulating insulin secretion, like a sulfonylurea. 
Adding a sulfonylurea to metformin has thus been the 
conventional and the gold standard combination therapy 
for decades. However, while previous therapeutic goals 
made this combination quite attractive, the lower gly-
cemic targets for intensiﬁ  cation of therapy substantially 
increase the risk of hypoglycemia (particularly in patients 
with mild hyperglycemia or in the older and more fragile 
patients) resulting in symptoms or increased food intake 
to avoid or treat them. Therefore, the need for more glu-
cose-sensitive agents as alternative combination therapies 
was warranted.
Recently, newer agents, which induce a glucose-
dependent stimulation of insulin secretion became available 
and can provide an attractive alternative for use in combi-
nation with metformin. Such a novel therapy for T2DM is 
based on pharmacological inhibition of the enzyme dipeptidyl 
peptidase IV (DPP-4), which is responsible for the rapid 
inactivation of the incretin hormones glucagon-like peptide-1 
(GLP-1) and glucose-dependent insulinotropic peptide (GIP) 
(Langley et al 2007). These intestinally derived peptides are 
released rapidly after eating, ie, in the presence of glucose 
or nutrients in the gut.
By stabilizing endogenous incretin hormones at physi-
ological concentrations, DPP-4 inhibitors increase the sensi-
tivity to glucose of both insulin and glucagon secretion (ie, 
increase insulin secretion and suppress glucagon secretion in a 
glucose-dependent manner), thereby lowering glucose levels. 
DPP-4 inhibitors are thus the ﬁ  rst oral agents addressing the 
dual α- and β- islet cells dysfunction present in T2DM.
This article provides an overview of the characteristics 
and combined anti-diabetic effects of the DPP4 inhibitor 
vildagliptin and metformin.Vascular Health and Risk Management 2008:4(3) 483
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Pharmacokinetics/
Pharmacodynamics (Pk/Pd) and 
mode of action (MoA) of metformin 
and vildagliptin, and rationale for 
their use in combination
PK/PD and MoA of metformin
Metformin is absorbed mainly from the small intestine, 
with a 60% bioavailability; the plasma half life is estimated 
at 1.5–4.9 hours. The drug is not signiﬁ  cantly metabolized, 
and 90% is eliminated unchanged in urine in 12 hours by 
glomerular ﬁ  ltration and tubular secretion. It is distributed 
in most tissues, with higher concentrations in liver, kidneys, 
salivary glands and the intestinal walls. The drug can be 
removed by hemodyalisis.
Metformin has been available for treating diabetes since 
the 1950s, but despite decades of medical use, the mecha-
nism of action of the drug at the molecular level is still not 
fully understood but is related to an action on AMP kinase 
(Goodarzi and Bryer-Ash 2005).
The glucose-lowering effect of metformin is mainly due 
to decreased basal hepatic glucose output and -to a lesser 
extent- enhanced peripheral glucose uptake (with muscle as 
its main site of action). The latter action on muscles is likely 
indirect and explained by the overall improved metabolic 
state. Additional actions that contribute to the glucose-
lowering effect are the increased intestinal use of glucose and 
decreased fatty acid oxidation (Bailey and Turner 1996).
The most feared and widely publicized adverse effect 
of biguanide therapy is lactic acidosis, likely resulting 
from the action of biguanides to interfere with non-oxida-
tive glucose metabolism. Lactic acidosis could occur in 
energy-compromised individuals leading to increased lactate 
production and/or reduced lactate clearance, such as in liver 
disease, renal dysfunction or other illness causing tissue 
hypoxia (such as cardiac or respiratory dysfunction). It has 
a high mortality, but is extremely rare with metformin, the 
overall incidence being estimated at one case per 30,000 
patient-years. This rate of lactic acidosis events is actually 
almost similar to that reported in patients with T2DM not 
taking metformin (Brown et al 1998) indicating that lactic 
acidosis occurs in metformin-treated patients when energy 
metabolism is further altered in patients where it was already 
severely compromised (Tahrani et al 2007).
The most common dose-limiting adverse effects of 
metformin are gastrointestinal (abdominal discomfort, 
metallic taste and anorexia, nausea or diarrhea) but these 
effects are minimized with gradual upward titration and 
concomitant administration with meals, overall leading to 
drug discontinuation in less than 5%–10% of the patients 
(Bailey and Turner 1996; Goodarzi and Bryer-Ash 2005). 
However gastrointestinal discomfort is often the single fac-
tor that prevents the use of higher, more efﬁ  cacious doses 
of metformin.
PK/PD and MoA of vildagliptin
Vildagliptin is well and rapidly absorbed after oral adminis-
tration. About 70% of the orally administered vildagliptin is 
metabolized, hydrolysis being the main pathway, and renal 
excretion being the main route of elimination (85%), with 
some of the oral dose excreted in the urine as unchanged drug 
(23%). Food ingestion does not alter the pharmacokinetics 
of vildagliptin (Sunkara et al 2007). Vildagliptin does not 
inhibit or induce the major P450 enzymes and shows no 
drug interactions with commonly used medication (such as 
glyburide, metformin, pioglitazone, digoxin, warfarin, sim-
vastatin, valsartan, amlodipine, ramipril) (Ayalasomayajula 
et al 2007; El Ouaghlidi et al 2007; He et al 2007a, b). Age, 
gender, BMI, and race do not affect the pharmacokinetics 
of vildagliptin (He et al 2007c, d, e).
Vildagliptin selectively inhibits DPP- 4 activity (Burkey 
et al 2006), resulting in increased levels (2- to 4-fold) of the 
two key glucoregulatory incretin hormones GLP-1 and GIP, 
allowing the pancreatic islet cells to better sense and more 
appropriately respond to raised glucose levels (Ahren et al 
2005; Mari et al 2005).
The increased levels of active endogenous incretin 
hormones result in better post-prandial and fasting glucose 
control by stimulating insulin secretion, reducing glucagon 
levels and suppressing overnight hepatic glucose production, 
which all contribute to the clinical effect to lower HbA1c 
(Ahren et al 2004b, 2005; Balas et al 2007).
Further evidence for an improvement of islet function 
with vildagliptin, with an increase of both α- and β-cell 
responsiveness to glucose, come from a number of recent 
studies (Azuma et al 2007; Pratley et al 2007b; Mari et al 
2007). In addition, vildagliptin treatment leads to a more 
efﬁ  cient β-cell insulin processing, providing further evi-
dence for an amelioration of the abnormal β-cell function 
in patients with T2DM (Ahren et al 2007). Previous data in 
rodents showed that vildagliptin increases pancreatic β-cell 
mass by markedly stimulating β-cell replication and inhibit-
ing apoptosis (Duttaroy et al 2005), similar to the beneﬁ  cial 
effects reported for parenterally administered GLP-1 agonists 
(Tourrel et al 2002). These animal data on beta cell protec-
tion still need to translate into durable glycemic control Vascular Health and Risk Management 2008:4(3) 484
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in humans, which can only be demonstrated in long term 
clinical trials.
These primary effects of vildagliptin to enhance incretin 
hormone levels also lead to improved insulin mediated glu-
cose disposal which may be due in part to reduced glucose 
toxicity and in part to reduced stored triglycerides in muscle 
and liver (Azuma et al 2007). A similar improvement in 
insulin sensitivity and β-cell function, leading to improved 
postprandial glycemia, has recently been shown in subjects 
with impaired fasting glucose after 6 weeks of treatment 
with vildagliptin 100 mg/day (Utzschneider et al 2008). 
Furthermore, the known effects of vildagliptin on incretin 
levels and islet function in type 2 diabetes were reproduced 
in another study conducted in 179 subjects with impaired 
glucose tolerance over 12 weeks, with a 32% reduction in 
postprandial glucose excursions and no evidence of hypo-
glycemia or weight gain (Rosenstock et al 2007c).
Vildagliptin shows no action on gastric emptying or 
any evidence for delayed glucose absorption or delayed 
appearance of drugs co-administered in interaction studies 
(Vella et al 2007).
Interestingly, treatment with vildagliptin for 4 weeks 
improved postprandial plasma triglyceride after a fat-rich 
meal, and this was achieved mainly through a decrease in 
intestinally derived apo B-48-containing particles. These 
results indicate that vildagliptin treatment reduces postpran-
dial atherogenic TRLs in the circulation and suggest that it 
may protect against weight gain in patients with T2DM by 
extracting less fat from the gut (Matikainen et al 2006).
The clinical proﬁ  le of vildagliptin has been extensively 
assessed in the development program, providing evidence of 
its glucose-lowering efﬁ  cacy across a wide range of clini-
cal uses: as monotherapy or initial combination therapy in 
treatment-naive patients (Dejager et al 2007; Pi-Sunyer et al 
2007; Rosenstock et al 2007 a, b; Schweizer et al 2007), as 
add-on therapy with the most commonly prescribed classes 
of oral hypoglycemic drugs (Bosi et al 2007; Garber et al 
2007a, b), and in combination with insulin in patients with 
long-standing disease (Fonseca et al 2007). In monotherapy, 
vildagliptin produced consistent reductions from baseline in 
HbA1c of approximately 1%, sustained out to one year, was 
weight-neutral and well-tolerated, and had a low incidence 
of hypoglycemia and no episodes of severe hypoglycemia. 
Vildagliptin 100 mg daily was as effective as rosiglitazone 
8 mg daily without the weight gain (Rosenstock et al 
2007b). When compared with metformin 2000 mg daily, 
statistical noninferiority was not established but treatment 
with vildagliptin 100 mg daily for 1 year reduced HbA1c by 
1.0% (p   0.001) with a more favorable gastrointestinal 
(GI) tolerability than metformin (Schweizer et al 2007). 
Furthermore, the efﬁ  cacy and safety proﬁ  les of vildagliptin in 
elderly patients (who had a high prevalence of co-morbidities 
and mild renal insufﬁ  ciency) were comparable to those in 
younger patients, including a very low (0.8%) incidence of 
hypoglycemia and no severe hypoglycemic episode (Pratley 
et al 2007a). In this regard, a recent study of vildagliptin added 
to existing insulin therapy is interesting: hypoglycemia was 
signiﬁ  cantly less frequent and less severe with vildagliptin 
than with placebo, despite improved glycemic control in 
those receiving vildagliptin (Fonseca et al 2007). In addition, 
recent data further conﬁ  rmed the low hypoglycemic risk at 
the other end of the disease spectrum. In recently diagnosed 
patients with mild hyperglycemia (n = 306; baseline HbA1c ≈ 
6.7%, FPG ≈ 7.1 mmol/L and nearly half of the patients over 
age 65) 52-week treatment with vildagliptin elicited a mod-
est but statistically signiﬁ  cant reduction in A1C (–0.3%), 
primarily due to a reduction of postprandial glucose and at 
least in part reﬂ  ecting improved beta-cell function. Treatment 
with vildagliptin was weight neutral (–0.5 kg from baseline) 
and was well tolerated with no episode of hypoglycemia over 
one year in the vildagliptin group (Scherbaum et al 2007). 
This low hypoglycemic potential of vildagliptin likely reﬂ  ects 
the glucose-dependent nature of both the insulinotropic and 
the glucagonostatic effects of GLP-1.
Rationale for the combination 
of vildagliptin and metformin
Because an incretin-based therapy acts by different mecha-
nisms than metformin, combined therapy with metformin 
and a DPP4 inhibitor like vildagliptin was expected to be 
of considerable interest for the treatment of type 2 diabetes. 
Firstly, additive effects on plasma glucose lowering should 
be seen, which was ﬁ  rst demonstrated with a combination 
of metformin and GLP-1 infusion in T2DM patients (Zander 
et al 2001). Furthermore, beyond the additive effects of the 
drugs, the attractive potential of this combination would be 
to achieve the glucose lowering effect with beneﬁ  cial effects 
on ß-cell function, without promoting weight gain or increas-
ing the risk of hypoglycemia and without exacerbating the 
GI side effects of metformin. Clinical studies have indeed 
conﬁ  rmed these expectations as outlined below.
An additional interesting aspect regarding the combination 
of metformin and a DPP4 inhibitor comes from the 
following recent research ﬁ  ndings. Firstly, it was indicated 
that metformin increases plasma active GLP-1 in obese 
nondiabetic subjects, suggesting that metformin may have the Vascular Health and Risk Management 2008:4(3) 485
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additional property of inhibiting DPP IV activity (Mannucci 
et al 2001). This increase in active GLP-1 with metformin 
was further conﬁ  rmed by a number of studies, while the 
underlying mechanism is still the subject of debate: the 
increase could reﬂ  ect a stimulation of GLP-1 secretion from 
intestinal L cells, an inhibition of renal GLP-1 excretion or 
an increased transcription/translation of the proglucagon 
gene, as well as an effective inhibition of DPP IV activity 
(Zander et al 2001; Hinke et al 2002 a, b; Green et al 2006; 
Lindsay et al 2005).
The clinical potential of this mechanistic research further 
emerged when Dunning et al (Dunning et al 2006) compared 
the effects of vildagliptin on plasma levels of intact GLP-1 
in drug-naïve patients with T2DM versus patients receiving 
concomitant metformin. Relative to patients receiving no 
concomitant OAD, the effects of vildagliptin to increase 
plasma levels of both fasting and postprandial active GLP-1 
were clearly and consistently enhanced in patients receiv-
ing concomitant metformin, a ﬁ  nding that likely extends to 
DDP4 inhibitors in general (Migoya et al 2007). The fact 
that vildagliptin substantially enhances the incretin effect 
in patients receiving concomitant metformin may underlie 
the pronounced efﬁ  cacy of vildagliptin to decrease FPG, 
PPG and HbA1c in metformin-treated patients, as further 
discussed below.
Clinical data on combination 
therapy of  vildagliptin 
and metformin
The efﬁ  cacy of a drug when combined with other agents 
can be different from that of the same drug prescribed as 
monotherapy: when used in combination, most drugs reduce 
HbA1c to a lesser extent than in monotherapy (DeFronzo and 
Goodman 1995). Furthermore, patients failing metformin 
monotherapy could have different characteristics and show 
a different response to hypoglycemic agents. Therefore, to 
reliably assess the efﬁ  cacy of a new drug in combination 
with metformin, it is important to get data in patients insuf-
ﬁ  ciently controlled with metformin monotherapy at stable, 
maximally tolerated doses. The efﬁ  cacy and safety of the 
vildagliptin/metformin combination was studied accordingly 
in 2 placebo-controlled and 1 active-controlled trials.
The combination of vildagliptin plus metformin was ini-
tially evaluated in a 12-week phase II study with a 40-week, 
double-blind, placebo-controlled extension (Ahren et al 
2004a). In this population starting from a relatively low base-
line HbA1c of 7.6% and treated with metformin for a mean 
duration of 28 months and at a mean daily dose of 1.8 g/day, 
vildagliptin 50 mg daily added to metformin reduced mean 
HbA1c by 1.1% relative to metformin/placebo after 52 weeks 
of treatment (p   0.001). This reﬂ  ected deterioration of gly-
cemic control in patients receiving metformin alone and a 
stable HbA1c of ~7.1% maintained from week 12 to week 52 
in patients treated with vildagliptin plus metformin, suggest-
ing that the addition of vildagliptin prevented the progressive 
deterioration in glucose control seen in patients treated with 
metformin/placebo (Figure 1). The percentage of patients 
achieving the target of HbA1c  7% at study end was 41.7% 
with vildagliptin plus metformin and 10.7% with placebo 
plus metformin (signiﬁ  cant between-group difference) and 
the percentage of patients achieving a target of  6.5% was 
21.4% with vildagliptin versus none with placebo. Two 
patients receiving vildagliptin during the core phase (out 
of 107 patients) experienced one episode of hypoglycemia 
and there were no hypoglycemic episodes during the exten-
sion. The lowering of fasting plasma glucose (FPG) from 
baseline persisted in patients who took vildagliptin 50 mg 
qd plus metformin, and was signiﬁ  cantly greater than in 
those taking placebo plus metformin (between group dif-
ference of 1.1 mmol/L). Body weight was unchanged with 
vildagliptin, showing no difference to placebo (+0.04 kg). 
Fasting triglycerides, as well as total and LDL cholesterol, 
were modestly improved with vildagliptin compared to 
placebo. Interestingly, additional analyses showed that 
the maintenance of efﬁ  cacy over 52 weeks was associated 
with a sustained improvement in both insulin secretion and 
dynamic insulin sensitivity (Ahren et al 2005). Furthermore, 
vildagliptin signiﬁ  cantly improved the efﬁ  ciency of insulin 
processing by the β-cells, providing further evidence that 
vildagliptin treatment ameliorates abnormal β-cell function 
in patients with T2DM (Ahren et al 2007).
The combination of vildagliptin plus metformin was further 
evaluated in a 24-week phase 3 study conducted in patients 
with inadequate glycemic control (HbA1c 7.5%–11%) despite 
a stable metformin dose ( 1500 mg/day, mean daily dose of 
2100 mg with a mean duration of metformin use of 17 months) 
(Bosi et al 2007). Enrollees were randomized to vildagliptin 
50 mg daily (given as 50 mg qd, n = 177), vildagliptin 
100 mg daily (given as 50 mg bid, n = 185), or placebo 
(n = 182). The demographic and diabetic background charac-
teristics of the 3 groups were well balanced at baseline, with a 
mean age of 54 years, a mean BMI of 32.8 kg/m2, a mean dis-
ease duration of 6.2 years and a mean HbA1c of 8.4% (Table 1). 
Relative to placebo the addition of vildagliptin to metformin 
resulted in signiﬁ  cant and dose-related reductions in HbA1c 
(–1.1 ± 0.1% and –0.7 ± 0.1% with vildagliptin 100 mg daily Vascular Health and Risk Management 2008:4(3) 486
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and 50 mg daily, respectively; p   0.001 vs placebo for both), 
and in fasting plasma glucose (–1.7 ± 0.3 mmol/L [p   0.001 
vs placebo] and –0.8 ± 0.3 mmol/L [p = 0.003 vs placebo], 
respectively). The percentage of patients achieving the target 
of HbA1c  7% at study end was 35.5% with vildagliptin 
100 mg daily plus metformin compared to 9.4% with placebo 
plus metformin and percentage of patients achieving a target 
of  6.5% was 18.2% with vildagliptin 100 mg daily plus 
metformin versus 3.1% with placebo plus metformin (both 
p   0.001). In addition, treatment with vildagliptin elicited 
signiﬁ  cant reductions from baseline in 2-hour postprandial 
glucose relative to placebo: –2.3 ± 0.6 mmol/L and –1.9 ± 
0.6 mmol/L with vildagliptin 100 mg and 50 mg daily 
(p = 0.001 vs placebo for both). Again, these effects were 
associated with signiﬁ  cant improvements in measures of 
β-cell function: the β-cell function index, expressed as insu-
lin secretory rate/glucose (Pratley et al 2007b), increased 
signiﬁ  cantly by 3-fold relative to placebo in both vildagliptin 
groups (p   0.001). In patients aged  65 years, a pre-planned 
subgroup analysis showed a mean reduction from baseline in 
HbA1c of 1.3 ± 0.2% with vildagliptin 100 mg/d compared to 
a small increase of 0.2 ± 0.1% with placebo.
Vildagliptin did not induce body weight gain (change from 
baseline of +0.21 and –0.38 kg with vildagliptin 100 and 50 
mg daily, respectively, compared to –1.02 kg with placebo). 
The effect of vildagliptin on fasting lipids was largely neutral, 
with the exception of fasting triglycerides, which increased 
less in the vildagliptin treatment groups than in the placebo 
group (difference from placebo ranging from 14.5% to 18.4%). 
Effects of vildagliptin 100 mg daily and placebo on blood pres-
sure (BP) were compared and showed modest improvements 
in BP in both groups with a signiﬁ  cant beneﬁ  t of vildagliptin 
versus placebo added to metformin (Bosi et al 2007b).
The incidence of reported adverse events (AEs) was 
similar among groups (65.0%, 63.3%, and 63.5% of patients 
receiving vildagliptin 100 mg daily, 50 mg daily, or placebo, 
respectively). GI side effects were reported less frequently 
in the vildagliptin treatment groups (14.8% and 9.6% in 
the 100- and 50-mg daily groups, respectively) than in the 
placebo group (18.2%). One patient in each of the 3 groups 
experienced a mild hypoglycemic event, which did not lead 
to discontinuation. Discontinuations due to AEs were overall 
marginally more frequent with vildagliptin (4.4% and 4.5% 
respectively with 100 and 50 mg/d) than placebo (2.2%) 
(not driven by any speciﬁ  c AE), while serious AEs (SAEs) 
were marginally more common with placebo (4.4%) than 
with vildagliptin (2.7% and 2.3% with 100 and 50 mg daily, 
respectively), and there were no deaths.
An additional active-controlled study (Bolli et al 2008) 
assessed the combination therapy of vildagliptin and met-
formin: a 24-week, multicenter, double-blind, randomized 
study, comparing vildagliptin (100 mg daily, given as 
equally-divided doses, n = 295) and pioglitazone (30 mg 
daily, given as a single qd dose, n = 281) in patients with 
Figure 1 Mean (± SE) HbA1c during 52-week treatment with vildagliptin (50 mg qd, closed triangles, n = 42) and placebo (open circles, n = 29) in metformin-treated patients 
with T2DM.  The between-group difference in HbA1c from baseline to endpoint was –1.1 ± 0.2% (p   0.0001) (Ahren et al 2004a). Copyright © American Diabetes Association. 
From Diabetes Care®, Vol. 27, 2004; 2874–80. Modiﬁ  ed with permission from The American Diabetes Association.Vascular Health and Risk Management 2008:4(3) 487
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inadequate glycemic control (HbA1c 7.5%–11%) despite 
metformin monotherapy (used for an average of 43 months) 
at a stable dose (mean dose at baseline  2000 mg/day).
The groups were well balanced at baseline, with a mean 
age, BMI, HbA1c, and FPG of ~57 years, 32.1 kg/m2, 8.4%, 
and 10.9 mmol/L, respectively. Patients were predomi-
nantly Caucasian, with mean disease duration of 6.4 years. 
When added to a stable dose of metformin, both vilda-
gliptin 100 mg and pioglitazone 30 mg daily were equally 
effective in decreasing HbA1c (by 0.9 ± 0.1% and 1.0 ± 0.1%, 
respectively) from identical baseline values (8.4 ± 0.1%) with 
statistical non-inferiority of vildagliptin to pioglitazone being 
established (Figure 2). The decrease in A1C in the pre-deﬁ  ned 
subgroup of patients with baseline A1C  9.0% was more 
substantial, as expected, and similar in vildagliptin-treated 
patients (baseline = 9.8%; mean change = –1.5 ± 0.2%) 
and in those receiving pioglitazone (baseline = 9.7%; mean 
change= –1.5 ± 0.2%). The percentage of patients who 
achieved the endpoint of HbA1c  6.5% was comparable 
in those receiving vildagliptin (19.7%) and pioglitazone 
(17.9%). Pioglitazone decreased FPG (–2.1 ± 0.1 mmol/L) to 
a greater extent than vildagliptin (1.4 ± 0.1 mmol/L), but only 
pioglitazone increased body weight (+1.9 ± 0.2 kg: between-
group difference = –1.6 ± 0.3 kg, p   0.001) (Figure 3). 
In the more obese patients (with BMI  35 kg/m2), the 
mean change in body weight from baseline to endpoint 
was +0.1 ± 0.5 kg in patients receiving vildagliptin 
(baseline =  110.6 kg, n  = 73),  and +2.6 ±  0.5 kg in 
pioglitazone-treated patients (baseline = 110.3 kg, n = 70; 
between-treatment difference –2.5 ± 0.7 kg [p   0.001]). On 
the other hand, the efﬁ  cacy tended to be more pronounced 
with pioglitazone in the obese patients (mean baseline BMI 
of 36 kg/m2) with a mean change in HbA1c of –1.2% ± 0.1% 
versus –0.8% ± 0.1% with vildagliptin, while the reverse was 
true in non obese patients (mean baseline BMI 27 kg/m2) 
in whom the decrease in HbA1c was somewhat greater in 
those receiving vildagliptin (1.0% ± 0.1%) than pioglitazone 
(0.7% ± 0.1%).
Fasting lipid levels were similar in the two treatment groups at 
baseline. Total-cholesterol, LDL-cholesterol and non-HDL cho-
lesterol decreased in patients receiving vildagliptin and increased 
in pioglitazone-treated patients (with between-group differences 
of –6.9% ± 1.3% for total cholesterol, –10.2% ± 2.4% for LDL 
cholesterol, and –4.9% ± 1.9% for non-HDL cholesterol, all 
p   0.001). Conversely, fasting triglycerides decreased more 
(between-treatment difference of 9.3% ± 3.2%, p = 0.004) and 
HDL-cholesterol increased more (between-treatment difference 
of −13.8% ± 1.6%, p   0.001) in pioglitazone-treated patients. 
AEs were reported by 60% of patients receiving vildagliptin 
and by 56.4% of pioglitazone-treated patients; SAEs were 
reported by 2.0% and 4.6% of patients receiving vildagliptin 
and pioglitazone, respectively. Mild hypoglycemia was reported 
by 1 patient in the vildagliptin group (0.3%) and by no patient 
receiving pioglitazone (Bolli et al 2008).
In summary, the 3 double-blind, controlled studies 
evaluating combination therapy with vildagliptin and 
metformin showed statistically signiﬁ  cant and clinically 
meaningful reductions in HbA1c when vildagliptin was added 
to metformin of ~1% (Figure 2), that were evident across all 
demographic and disease subgroups. In patients with T2DM 
Table 1 Patients’ baseline characteristics: addition of vildagliptin in patients with inadequate glycemic control on maximum tolerated 
doses of metformin alone
Study 1a
Extension population
Study 2b
Randomized population
Study 3c
Randomized population
Vilda 50 mg 
qd + Met
PBO + Met Vilda 50 mg 
qd + Met
Vilda 50 mg 
bid + Met
PBO + Met Vilda 50 mg 
bid + Met
Pio 30 mg 
qd + Met
N 42 29 143 143 130 295 281
Age (years)
(mean ± SD)
58.4 ± 9.2 54.3 ± 12.2 54.3 ± 9.7 53.9 ± 9.5 54.5 ± 10.3 56.3 ± 9.3 57.0 ± 9.7
Male/Female (%) 62/38 76/24 57/43 62/38 53/47 62/38 64/36
BMI (kg/m2)
(mean ± SD)
29.6 ± 3.7 29.9 ± 3.6 32.1 ± 5.3 32.9 ± 5.0 33.2  ± 6.1 32.2 ± 5.6 32.1 ± 5.1
HbA1c (mean ± SD) 7.6 ± 0.6 7.8 ± 0.6 8.4 ± 0.9 8.4 ± 1.0 8.3 ± 0.9 8.4 ± 1.0 8.4 ± 0.9
FPG (mmol/L)
(mean ± SD)
9.6 ± 1.6 10.1±1.8 9.7 ± 2.2 9.9 ± 2.56 10.0  ± 2.35 10.9 ± 2.6 11.0 ± 2.7
Duration of T2DM
(years) (mean ± SD)
5.8 ± 4.2 4.6 ± 3.6 6.8 ± 5.5 5.8 ± 4.7 6.2 ± 5.3 6.4 ± 4.9 6.4 ± 5.2
aStudy 1:   A 52-week study of vildagliptin 50 mg daily added to metformin (Ahren et al 2004a).
bStudy 2:   A 24-week study of vildagliptin (50 mg daily or 100 mg daily) or placebo added to metformin (Bosi et al 2007a).
cStudy 3:   A 24-week study of vildagliptin (100 mg daily) or pioglitazone (30 mg daily) added to metformin (Bolli et al 2008).
Abbreviations: Vilda, vildagliptin; Met, metformin; PBO, placebo; Pio, pioglitazone.Vascular Health and Risk Management 2008:4(3) 488
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inadequately controlled with metformin, the addition of 
vildagliptin (100 mg daily) was equally effective as that of 
pioglitazone (30 mg daily). Efﬁ  cacy was well preserved over 
52 weeks in the placebo-controlled extension. Fasting and post 
prandial plasma glucose were signiﬁ  cantly reduced; and the 
beneﬁ  cial effects on glucose control was clearly accompanied 
by consistent improvements of parameters for β-cell function. 
The effects on fasting lipids were neutral and, in contrast to the 
pioglitazone/metformin combination (especially in the more 
obese patients) there was no weight gain. Overall the tolerabil-
ity proﬁ  le was good, with in particular no exacerbation of GI 
tolerability and there was no increased risk of hypoglycemia 
with vildagliptin and metformin combination therapy.
Vildagliptin as a ﬁ  xed combination 
product with metformin – 
opportunities for improvement 
of adherence
While early and aggressive treatment with multiple drug com-
binations becomes increasingly common in the management 
of T2DM, adding more medications may however translate 
into reduced adherence to treatment. Subsequently, efforts 
have been made to simplify the treatment regimen with ﬁ  xed-
combination tablets to help improving treatment adherence 
in patients with T2DM who frequently take multiple medica-
tion. For this reason, vildagliptin and metformin have recently 
been made available in a single tablet (Eucreas®).
This new galenical formulation combines ﬁ  xed doses of 
vildagliptin and metformin in 2 dosage strengths of 50/850 
and 50/1000 mg of vildagliptin and metformin, and was 
developed based on 4 additional pharmacokinetic (PK) stud-
ies: 3 cross-over design PK studies in healthy subjects, to 
assess if the ﬁ  xed combination tablet was bioequivalent to the 
free combination of the active components, and 1 cross-over 
design PK study to assess the effect of food on the absorption 
of the ﬁ  xed combination tablet.
These PK studies demonstrated that the ﬁ  xed combination 
tablets are bioequivalent to the co-administered vildagliptin 
and metformin as free combinations. The efﬁ  cacy and safety 
of the new combination tablet can thus be based on the data 
already available in T2DM patients insufﬁ  ciently controlled 
with metformin monotherapy.
What is known with compliance 
to OADs
Poor adherence to a treatment regimen is common (Osterberg 
and Blaschke 2005). At least 50% of patients do not fully 
beneﬁ  t from their treatment due to inadequate compliance. 
This contributes to explain the gap between the implemen-
tation of clinical guidelines and the expected beneﬁ  ts. Poor 
compliance is a particular problem in asymptomatic and 
chronic diseases such as T2DM (Cramer 2004) contributing 
to substantial increases in morbidity and cost, with a higher 
risk of hospitalizations (Balkrishnan et al 2003; Lau and Nau 
2004). In T2DM, poor medication adherence is associated 
with inadequate glycemic control ( Schectman et al 2002; 
Pladevall et al 2004): even after adjusting for demographic 
and clinical characteristics, a 10% decrease in adherence to 
Figure 2 Study 2 – Adjusted mean change from baseline to endpoint in HbA1c after 24 weeks of treatment with vildagliptin (50 mg bid) or placebo in metformin-treated 
patients with T2DM (p   0.001) (Bosi et al 2007a).
Study 3 – Adjusted mean change from baseline to endpoint in HbA1c after 24 weeks of treatment with vildagliptin (50 mg bid) or pioglitazone (30 mg qd) in metformin-treated 
patients with T2DM; the between group difference was 0.10 ± 0.08% (95 CI: −0.05, −0.26) (Bolli et al 2008).Vascular Health and Risk Management 2008:4(3) 489
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metformin was signiﬁ  cantly associated with an increase of 
0.14% in HbA1c (Pladevall et al 2004).
Among all the factors potentially related to adherence 
(including demographic, psychological, social, health care 
provider and medical system factors), polypharmacy and the 
complexity of a regimen (with the number of dose-adminis-
trations) are known to be 2 important determinants of poor 
compliance (Paes et al 1997; Balkrishnan et al 2003). Dia-
betic patients are frequently polymedicated, especially older 
patients with multiple co morbidities (Pratley et al 2007a). 
They most often need medications for cardioprotection, hyper-
tension and hyperlipidemia in addition to diabetes. While the 
question whether this polypharmacy adversely affects adher-
ence among diabetic patients is still under some debate (Grant 
et al 2003), most studies have shown that reducing the pill 
burden resulted in improved compliance (Dezii et al 2002; 
Melikian et al 2002; Kardas 2005; Bangalore et al 2007). In 
particular, a large prospective study that evaluated compliance 
based on self reported standard questionnaire has suggested 
the relevance of reducing the daily dosing frequency of oral 
antidiabetic agents, in order to improve compliance and 
metabolic control (Guillausseau 2003).
Therefore, one practical way of enhancing adherence is to 
make the treatment regimen simpler with ﬁ  xed-combination 
products. Given the importance of medication adherence for 
health outcomes of diabetes care (Pladevall et al 2004), it is 
surprising that only few studies have looked at the effects 
on adherence of ﬁ  xed combination drugs versus individual 
drugs. One recent meta-analysis (which included 2 studies 
in the diabetic population) showed that ﬁ  xed-dose combina-
tion reduce the risk of non-compliance by 26% compared to 
free-drug combination regimens (pooled relative risk [RR] 
0.74; 95% conﬁ  dence interval [CI], 0.69–0.80; p   0.0001) 
(Bangalore et al 2007).
Thus, ﬁ  xed-dose combination tablets may play an impor-
tant role in T2DM to help improving medication compliance 
and the effectiveness of therapy, which should ultimately 
translate into better clinical outcomes.
Conclusions and place in therapy
The combination of vildagliptin and metformin, two oral anti-
diabetic agents with complementary mechanisms of action, 
provides superior efﬁ  cacy and allows more patients to reach 
their glycemic targets compared to continuing metformin 
monotherapy, without increasing the risk of hypoglycemia, 
without exposing to weight gain and without altering common 
cardiovascular risk factors (hypertension and lipid proﬁ  le). In 
addition, this combination has demonstrated favorable effects 
on pancreatic α- and β-cells. Whether the effect on parameters 
of β-cell function will translate in long term ß-cell preserva-
tion, which may modify the course of the disease, remains 
to be shown by long-term clinical studies. The availability of 
vildagliptin and metformin in a single tablet (Eucreas®) further 
enhances convenience and likely adherence to treatment.
As the glycemic targets recommended by guidelines are 
further lowered, many patients may remain inadequately 
Figure 3 Study 3 – Time-course of mean body weight during 24-week treatment with vildagliptin (50 mg bid, closed triangles, n = 264) or pioglitazone (30 mg qd, open circles, 
n = 246) in T2DM patients continuing their previous stable metformin dose regimen (Derived from data of Bolli et al 2008).Vascular Health and Risk Management 2008:4(3) 490
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treated because of the various limitations of the current 
therapies, such as the increased risk of hypoglycemia with 
sulfonylureas or the weight gain with TZDs.
Given its characteristics, Eucreas® will be a particularly 
appealing treatment option for moderately hyperglycemic 
patients who are relatively close to target (ie, HbA1c between 
6.5 to 7.5% despite metformin) but for whom glucose control 
is not further tightened in order to avoid hypoglycemia or to 
limit weight gain. This new ﬁ  xed-combination of vildagliptin 
and metformin could thus take a promising place in therapy 
and become the preferred combination with metformin in 
these mildly hyperglycemic patients and in older and more 
fragile individuals.
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